BioSig to Highlight New Data from the PURE EP™ Platform at Heart Rhythm 2023
Leading physicians from Cleveland Clinic to present data from three posters that showcase the Company’s novel PURE EP™ Platform
Westport, CT, May 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it will be presenting data at Heart Rhythm 2023, the Heart Rhythm Society's 44th annual meeting, on May 19-21, 2023, in New Orleans, Louisiana. At the meeting, new clinical data collected by the Company’s PURE EP™ Platform will be highlighted in three posters, presented by leading physicians from Cleveland Clinic.
BioSig will also be exhibiting at booth #2045 where the Company’s executive leadership, clinical and commercial teams will share customizable features and algorithms of the PURE EP™ Platform, showcasing intracardiac signal specificity unavailable on any other signal technology platform.
Abstract and presentation details follow:
Friday, May 19, 2023 | 2:30-4:30 PM CT
Abstract: Unipolar Signal Modification-Guided Radiofrequency Ablation
Presenting Physician: Hagai Yavin, M.D., Research Fellow, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
First Author: Chadi Tabaja, MD
Saturday, May 20, 2023 | 1:30-3:30 PM CT
Abstract: Feasibility of Unipolar Signal Guided Ablation in Creating Contiguous Lines of Conduction Block: A Proof-of-Concept Study
Presenting Physician: Hagai Yavin, M.D., Research Fellow, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
First Author: Hagai Yavin, MD
DATE: TBD
Abstract: Comparison of Unipolar Electrogram Monitoring during Radiofrequency ablation in Viable and Ablated Myocardium: Loss of the S-component
Presenting Physician: TBD
First Author: Hagai D Yavin, MD
About Heart Rhythm 2023
The Heart Rhythm Society's annual Heart Rhythm meeting convenes 7,700+ of the world’s finest clinicians, scientists, researchers, and innovators in the field of cardiac pacing and electrophysiology. More than 700 international experts in the field will serve as faculty for the 200+ educational sessions, forums, symposia, and ceremonies, while 120+ exhibitors will showcase innovative products and services. To learn more, visit heartrhythm.com.
About The PURE EP™ Platform
The PURE EP™ Platform is a unique combination of proprietary hardware and software that enables the real-time acquisition of raw signal data—absent of unnecessary noise or interference—allowing physicians to make informed clinical decisions based on clear and precise data. With the heightened visualization of active signals, the PURE EP™ Platform is facilitating personalized patient care and innovations in the field of electrophysiology. In a recently published in the Journal of Cardiovascular Electrophysiology, electrophysiologists rated PURE EP™ as equivalent or superior to conventional systems for 93.6% of signal samples, with 75.2% earning a superior rating.
is currently in a national commercial launch and an integral part of well-respected healthcare systems, such as Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute.
About BioSig Technologies, Inc.
is an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare’s biggest priorities—saving time, saving costs, and saving lives.
The Company’s first product, the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.
The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate.1
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at . The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
1 Global Market Insights Inc. March 08, 2022
Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 55 Greens Farms Road, 1st Floor Westport, CT 06880 203-409-5444, x133
